Diabetes Mellitus News and Research RSS Feed - Diabetes Mellitus News and Research

Diabetes mellitus is a severe and debilitating chronic disease that develops in nearly 5 percent of the world’s population. People with this disease have a shortage of insulin or a reduced ability to use insulin, the hormone regulating blood glucose levels, which is normally produced by the pancreas. In the United States alone, an estimated 18 million people have diabetes, and each year about 1 million Americans are diagnosed with the disease. It is the sixth leading cause of death in the US and is responsible for over 200,000 deaths a year. Insulin-dependent (type I) diabetes accounts for around 10% of diabetics. For those patients, suffering from an inability of their pancreas to produce insulin, the only practical treatment possible is regular insulin replacement by multiple daily injections. Transplantation of a pancreas or pancreatic tissue would be beneficial to millions of such patients in that it would restore their normal ability to produce self insulin. Transplantation of human pancreas or pancreatic islets is a practiced and time-honored such therapeutic approach, but is extremely limited by the severe shortage of human donor organs. Tissera's R&D efforts in this domain are directed towards the development of a universally available and reliable source of animal fetal donor pancreatic precursor tissue, suitable for transplantation and eventual normal structural and functional growth in human diabetics.
Latest online version of German Diabetes Risk Score optimized for mobile devices

Latest online version of German Diabetes Risk Score optimized for mobile devices

The German Institute of Human Nutrition has updated the online version of its German Diabetes Risk Score and has optimized it for mobile devices. [More]
Kidney transplant recipients with inflammation prior to surgery more likely to develop diabetes

Kidney transplant recipients with inflammation prior to surgery more likely to develop diabetes

Up to 30 percent of people who receive organ transplants will develop diabetes, but researchers are unsure why. Although doctors typically blame immunosuppressive drugs that transplant recipients take to prevent organ rejection, it's unclear why some people develop the lifelong disorder, while others do not. [More]
Fixed-dose combination of sacubitril and valsartan for heart failure shows differing added benefit

Fixed-dose combination of sacubitril and valsartan for heart failure shows differing added benefit

The fixed-dose combination of sacubitril and valsartan (trade name: Entresto) has been approved since November 2015 for adults with symptomatic chronic heart failure with reduced pump function. [More]
MPC outperforms PID in automated insulin delivery for patients with type 1 diabetes mellitus

MPC outperforms PID in automated insulin delivery for patients with type 1 diabetes mellitus

The so-called artificial pancreas — an automated insulin delivery system for people with type 1 diabetes mellitus — uses an advanced control algorithm to regulate how much insulin a pump should deliver and when. Regulating glucose is challenging because levels respond to a wide-array of variables, including food, physical activity, sleep, stress, hormones, metabolism and more. [More]
New PsA-comorbidity index may help identify patients at risk of hospitalisation and premature death

New PsA-comorbidity index may help identify patients at risk of hospitalisation and premature death

The results of a study presented today at the European League Against Rheumatism Annual Congress showed that a newly developed method of evaluating the impact of different comorbidities in patients with Psoriatic Arthritis (PsA) can be used to prospectively identify those PsA patients at greater risk of hospitalisation and premature death. [More]
Study finds no added benefit of empagliflozin alone or in combination for type 2 diabetes

Study finds no added benefit of empagliflozin alone or in combination for type 2 diabetes

Empagliflozin has been approved since May 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycaemic control. [More]
Innovative model identifies T2D trajectory and related risks

Innovative model identifies T2D trajectory and related risks

An innovative model for determining a person's risk of developing type 2 diabetes (T2D) overcomes many of the challenges associated with estimating the onset of a chronic condition based on the usual sequence of comorbid conditions that lead up to a diagnosis of T2D. [More]
Accumulation of gut bacterial metabolite may lead to serious health problems in CKD patients

Accumulation of gut bacterial metabolite may lead to serious health problems in CKD patients

In patients with chronic kidney disease (CKD), the accumulation of a gut bacterial metabolite that's normally excreted in urine may contribute to serious health problems. The findings come from a study appearing in an upcoming issue of the Journal of the American Society of Nephrology. [More]
Simple sarcopenia screening method could easily diagnose severity of heart disease

Simple sarcopenia screening method could easily diagnose severity of heart disease

Researchers from Kumamoto University in Japan have shown that a simple screening method could quickly and easily diagnose the severity of heart disease. The method was originally developed to diagnose sarcopenia, a disease that causes a loss of muscle mass and strength. [More]
OSA patients may have 1.57 times more MACCE risk afer unplanned revascularization

OSA patients may have 1.57 times more MACCE risk afer unplanned revascularization

In an ongoing prospective study involving 1,311 patients from five nations, researchers found that untreated obstructive sleep apnea (OSA) was associated with increased risk of a Major Adverse Cardiac and Cerebrovascular Event (MACCE) -- cardiovascular death, non-fatal myocardial infarction (heart attack), non-fatal stroke, and unplanned revascularization such as heart bypass surgery and angioplasty. [More]
Oral regimens could offer simple solution for severe hyperglycaemia

Oral regimens could offer simple solution for severe hyperglycaemia

Study findings indicate that oral treatments could offer a simpler alternative to upfront insulin for patients who have severe hyperglycaemia at the time of diagnosis with Type 2 diabetes. [More]
Diabetic patients at risk for developing retinal diabetic neuropathy

Diabetic patients at risk for developing retinal diabetic neuropathy

A University of Iowa-led study of diabetes-related vision impairment holds good news -- and some bad news -- for patients with signs of these disorders. [More]
Tecnalia's transparent bioadjesive gel could treat diabetic foot ulcers

Tecnalia's transparent bioadjesive gel could treat diabetic foot ulcers

Tecnalia's Pharmaceutical Development laboratory conducts the selection of the candidate polymers and topical antiseptics necessary to obtain a stable, safe and effective formula in the form of a transparent bioadjesive gel specific for the treatment of diabetic foot ulcers. [More]
Obesity and diabetes during pregnancy can cause excessive growth of foetus

Obesity and diabetes during pregnancy can cause excessive growth of foetus

A recent study conducted by researchers at the University of Cambridge showed that obese women who develop gestational diabetes have a five-fold greater risk of excessive foetal growth at 6 months gestation. Furthermore, it revealed that such excessive growth starts before women are screened for gestational diabetes. [More]
Better management of blood sugar, blood pressure and LDL-cholesterol levels could reduce cardiovascular risk

Better management of blood sugar, blood pressure and LDL-cholesterol levels could reduce cardiovascular risk

While controlling blood pressure, blood sugar and LDL-cholesterol levels reduces the risk of cardiovascular disease in people with diabetes, only 7 percent of diabetic participants in three major heart studies had recommended levels of these three factors, according to research from the Heart Disease Prevention Program at the University of California, Irvine School of Medicine. [More]
Increased consumption of antibiotics in childhood may lead to adolescent prediabetes

Increased consumption of antibiotics in childhood may lead to adolescent prediabetes

Young children who take antibiotics may disrupt their gut's microbial ecosystem and be more likely to develop prediabetes in adolescence, new research from Greece reports. The study results will be presented in a poster Sunday, April 3, at ENDO 2016, the annual meeting of the Endocrine Society, in Boston. [More]
Study: Age and gender affects prevalence of certain peripheral vascular diseases

Study: Age and gender affects prevalence of certain peripheral vascular diseases

New findings from large-scale studies of more than 3.6 million people who underwent screening for cardiovascular disease reveals that a person's age and gender affects the prevalence of certain types of peripheral vascular diseases (PVD), and that diabetes is a major risk factor for developing these diseases, even in patients without heart disease. [More]
Preventing blindness through portable eye examinations: an interview with Dr Mario Ettore Giardini

Preventing blindness through portable eye examinations: an interview with Dr Mario Ettore Giardini

The number of blind people is high. In 2010, the World Health Organisation estimated that, throughout the world, approximately 39 million people are blind. [More]
Scientists explore new strategies to prevent onset of type 1 diabetes

Scientists explore new strategies to prevent onset of type 1 diabetes

Type 1 diabetes affects 30,000 individuals throughout Germany and is the most common metabolic disease in children and adolescents. To halt the ever-increasing incidence, the young investigator group "Immunological Tolerance in Type 1 Diabetes" at the Institute of Diabetes Research directed by Prof. Dr. Anette-Gabriele Ziegler is exploring new strategies to prevent the onset of the disease. [More]
Orexigen Therapeutics, Valeant Pharmaceuticals sign distribution agreement for Mysimba

Orexigen Therapeutics, Valeant Pharmaceuticals sign distribution agreement for Mysimba

Orexigen Therapeutics, Inc. today announced Valeant Pharmaceuticals International, Inc. will commercialize Mysimba (naltrexone HCl / bupropion HCl prolonged release) in Central and Eastern Europe. [More]
Advertisement